BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Mei WQ, Hu HZ, Liu Y, Li ZC, Wang WG. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis. World J Gastroenterol 2015; 21(19): 6044-6051 [PMID: 26019471 DOI: 10.3748/wjg.v21.i19.6044]
URL: https://www.wjgnet.com/1007-9327/full/v21/i19/6044.htm
Number Citing Articles
1
Anna Pękala, Rafał Filip. Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population StudyJournal of Clinical Medicine 2021; 10(22): 5311 doi: 10.3390/jcm10225311
2
Masafumi Nishio, Yoshito Ishii, Yu Hashimoto, Haruka Otake, Tsuyoshi Ogashiwa, Saya Tsuda, Hisae Yasuhara, Yusuke Saigusa, Hideaki Kimura, Shin Maeda, Reiko Kunisaki. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitisScandinavian Journal of Gastroenterology 2018; 53(10-11): 1236 doi: 10.1080/00365521.2018.1511825
3
Sean Stern, Alexandra J. Ward, Catherine Saint-Laurent Thibault, Fernando Camacho, Elham Rahme, Dominik Naessens, Guy Aumais, Edmond-Jean Bernard, Raymond Bourdages, Albert Cohen, Pierre Pare, Peter Dyrda. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulationJournal of Medical Economics 2018; 21(1): 27 doi: 10.1080/13696998.2017.1371033
4
Caroline Meyer Olesen, Mehmet Coskun, Laurent Peyrin-Biroulet, Ole Haagen Nielsen. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseasesPharmacology & Therapeutics 2016; 159: 110 doi: 10.1016/j.pharmthera.2016.01.001
5
S. Renna, E. Orlando, F. S. Macaluso, M. Maida, M. Affronti, M. Giunta, C. Sapienza, G. Rizzuto, R. Orlando, M. Dimarco, M. Cottone, A. Orlando. Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitisAlimentary Pharmacology & Therapeutics 2016; 44(3): 310 doi: 10.1111/apt.13692
6
N. N. Potekaev, O. V. Zhukova, S. I. Artemyeva. Psoriasis: a personalized approach to therapy. The preferred choice of systemic agents considering comorbid pathologiesMeditsinskiy sovet = Medical Council 2020; (12): 28 doi: 10.21518/2079-701X-2020-12-28-34
7
Hélène Vallet, Pascal Seve, Lucie Biard, Jean Baptiste Fraison, Philip Bielefeld, Laurent Perard, Boris Bienvenu, Sébastien Abad, Aude Rigolet, Alban Deroux, Damien Sene, Antoinette Perlat, Isabelle Marie, Elodie Feurer, Eric Hachulla, Olivier Fain, Gaëlle Clavel, Sophie Riviere, Pierre-Alban Bouche, Julie Gueudry, Gregory Pugnet, Phuc Le Hoang, Matthieu Resche Rigon, Patrice Cacoub, Bahram Bodaghi, David Saadoun. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis NetworkArthritis & Rheumatology 2016; 68(6): 1522 doi: 10.1002/art.39667
8
Cristina Trigo-Vicente, Vicente Gimeno-Ballester, Raquel Montoiro-Allué, Alejandro López-Del Val. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in SpainExpert Review of Pharmacoeconomics & Outcomes Research 2018; 18(3): 321 doi: 10.1080/14737167.2018.1411193
9
Katerina Pantavou, Anneza I Yiallourou, Daniele Piovani, Despo Evripidou, Silvio Danese, Laurent Peyrin-Biroulet, Stefanos Bonovas, Georgios K Nikolopoulos. Efficacy and safety of biologic agents and tofacitinib in moderate‐to‐severe ulcerative colitis: A systematic overview of meta‐analysesUnited European Gastroenterology Journal 2019; 7(10): 1285 doi: 10.1177/2050640619883566
10
Brigida Barberio, Fabiana Zingone, Leonardo Frazzoni, Renata D’Incà, Maria Chiara Maccarone, Matteo Ghisa, Davide Massimi, Greta Lorenzon, Edoardo Vincenzo Savarino. Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort StudyDigestive Diseases 2021; 39(1): 16 doi: 10.1159/000508865
11
Adrian D. Vickers, Claire Ainsworth, Reema Mody, Annika Bergman, Caroline S. Ling, Jasmina Medjedovic, Michael Smyth, John Green. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative ColitisPLOS ONE 2016; 11(10): e0165435 doi: 10.1371/journal.pone.0165435
12
Scott M. Whitlock, Clinton W. Enos, April W. Armstrong, Alice Gottlieb, Richard G. Langley, Mark Lebwohl, Joseph F. Merola, Caitriona Ryan, Michael P. Siegel, Jeffrey M. Weinberg, Jashin J. Wu, Abby S. Van Voorhees. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis FoundationJournal of the American Academy of Dermatology 2018; 78(2): 383 doi: 10.1016/j.jaad.2017.06.043
13
Yiru Zhou, Ruihua Fan, Benson O. A. Botchway, Yong Zhang, Xuehong Liu. Infliximab Can Improve Traumatic Brain Injury by Suppressing the Tumor Necrosis Factor Alpha PathwayMolecular Neurobiology 2021; 58(6): 2803 doi: 10.1007/s12035-021-02293-1
14
Sara Renna, Filippo Mocciaro, Marco Ventimiglia, Rosalba Orlando, Fabio Salvatore Macaluso, Maria Cappello, Walter Fries, Marco Mendolaro, Antonino Carlo Privitera, Concetta Ferracane, Valentina Pisana, Antonio Magnano, Dario Pluchino, Gaetano Inserra, Giuseppe Scarpulla, Serena Garufi, Antonio Carroccio, Sebastiano Siringo, Roberto Di Mitri, Mario Cottone, Ambrogio Orlando. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysisDigestive and Liver Disease 2018; 50(12): 1292 doi: 10.1016/j.dld.2018.06.008
15
Gabriele Dragoni, Marco Le Grazie, Beatrice Orlandini, Francesca Rogai. Golimumab in inflammatory bowel diseases: present and future scenariosClinical Journal of Gastroenterology 2019; 12(1): 1 doi: 10.1007/s12328-018-0906-9
16
Cristina Trigo-Vicente, Vicente Gimeno-Ballester, Santiago García-López, Alejandro López-Del Val. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitisInternational Journal of Clinical Pharmacy 2018; 40(6): 1411 doi: 10.1007/s11096-018-0743-4
17
A. Cholapranee, G. S Hazlewood, G. G. Kaplan, L. Peyrin-Biroulet, A. N. Ananthakrishnan. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trialsAlimentary Pharmacology & Therapeutics 2017; 45(10): 1291 doi: 10.1111/apt.14030